References
A. Garmendia Madiaraga, S. Santos Palacios, F. Guillén-Grima, J.C. Galofré, The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 923–931 (2014)
J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein, J.I. Mechanick, R. Pessah-Pollack, P.A. Singer, K.A. Woeber; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults, Clinical practice guidelines for hypothyroidism for hypothyroidism in adults: cosponsored by the American association of clinical endocrinologists and the American thyroid association. Endocr. Pract. 18, 988–1028 (2012)
P. Colucci, C. Seng Yue, M. Ducharme, S. Benvenga, A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur. Endocrinol. 9, 40–47 (2013)
S. Benvenga, When thyroid hormone replacement is ineffective? Curr. Opin. Endocrinol. Diabetes Obes. 20, 467–477 (2013)
G. Ianiro, F. Mangiola, T.A. Di Rienzo, S. Bibbò, F. Franceschi, A.V. Greco, A. Gasbarrini, Levothyroxine absorption in health and disease, and new therapeutic perspectives. Eur. Rev. Med. Pharmacol. Sci. 18, 451–456 (2014)
C. Cappelli, I. Pirola, L. Daffini, A. Formenti, C. Iacobello, A. Cristiano, E. Gandossi, E. Agabiti Rosei, M. Castellano, A double-blind placebo-controlled trial of liquid thyroxine ingested at breakfast: results of the TICO study. Thyroid 26, 197–202 (2016)
R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43, 154–160 (2013)
R. Vita, S. Benvenga, Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. Endocr. Pract. 20, e38–e41 (2014)
R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J. Clin. Endocrinol. Metab. 99, 4481–4486 (2014)
P. Fallahi, S.M. Ferrari, S. Camastra, U. Politti, I. Ruffilli, R. Vita, G. Navarra, S. Benvenga, A. Antonelli, TSH normalization in bariatric surgery patients after the switch from L-thyroxine in tablet to an oral liquid formulation. Obes. Surg. 27(1), 78–82 (2017)
R. Vita, P. Fallahi, A. Antonelli, S. Benvenga, The administration of L-thyroxine as soft gel capsule or liquid solution. Expert. Opin. Drug Deliv 11, 1103–1111 (2014)
C. Virili, P. Trimboli, F. Romanelli, M. Centanni, Liquid and softgel levothyroxine use in clinical practice: state of the art. Endocrine 54, 3–14 (2016)
A.M. Formenti, G. Mazziotti, R. Giubbini, A. Giustina, Treatment of hypothyroidism: all that glitters is gold? Endocrine 52, 411–413 (2016). doi:10.1007/s12020-016-0882-0
C.S. Yue, C. Scarsi, M.P. Ducharme, Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung 62, 631–636 (2012)
A.H. Shojaei, Buccal mucosa as a route for systemic drug delivery: a review. J. Pharm. Pharm. Sci. 1, 15–30 (1998)
J.A. Bartlett, K. van der Voort Maarschalk, Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine. AAPS PharmSciTech. 13, 1110–1115 (2012)
J.H. McDermott, A. Coss, C.H. Walsh, Celiac disease presenting as resistant hypothyroidism. Thyroid 15, 386–388 (2005)
T. Amer, R. David, S.E. Oberfield, Necrotizing enterocolitis and hypothyroidism in a newborn infant: treatment with intravenous L-thyroxine. Am. J. Perinatol. 11, 30–32 (1994)
B. Jauk, P. Mikosch, H.J. Gallowitsch, E. Kresnik, M. Molnar, I. Gomez, P. Lind, Unusual malabsorption of levothyroxine. Thyroid 10, 93–95 (2000)
L. Wartofsky, Myxedema coma. In Werners and Ingbar’s The Thyroid: A Fundamental and Clinical Text, ed. by L.E. Braverman, R.D. Utiger. (Lippincott Williams & Wilkins, Philadelphia, 2000), pp. 843–847
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
S.B. was an invited speaker at symposia organized by IBSA. The other authors declare no competing interests.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Benvenga, S., Di Bari, F. Intestinal absorption and buccal absorption of liquid levothyroxine. Endocrine 58, 591–594 (2017). https://doi.org/10.1007/s12020-017-1250-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-017-1250-4